Ignite Creation Date:
2024-05-05 @ 5:32 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00472693
Status:
COMPLETED
Last Update Posted:
2020-04-09
First Post:
2007-05-11
Brief Title:
Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
Sponsor:
Abramson Cancer Center at Penn Medicine
Organization:
Abramson Cancer Center at Penn Medicine
Organization Data
Organization:
Abramson Cancer Center at Penn Medicine
Class:
OTHER
Study ID:
UPCC 02106
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Genentech Inc | INDUSTRY |